{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:11:27Z","timestamp":1794442287181,"version":"4.9.1"},"reference-count":40,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Dexcom, Inc","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2025,9,29]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This analysis investigated whether use of real-time continuous glucose monitoring (CGM) compared with blood glucose monitoring (BGM) results in rapidly improved glycemic management in adults with type 2 diabetes (T2D) treated with basal insulin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research design and methods<\/jats:title>\n                    <jats:p>\n                      Using data from the MOBILE study where adults (n=175) with T2D treated with basal insulin without prandial insulin were randomized (2:1) to either CGM (n=116) or BGM (n=59), the treatment effect on glycemic management was determined over 3 months. The main outcome was a between-group difference in hemoglobin A\n                      <jats:sub>1c<\/jats:sub>\n                      (HbA\n                      <jats:sub>1c<\/jats:sub>\n                      ) at 3 months adjusted for baseline value. Other outcomes included changes in CGM-derived glucose metrics and hypoglycemic events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 3 months, there was a greater reduction from baseline in mean HbA\n                      <jats:sub>1c<\/jats:sub>\n                      in the CGM group compared with the BGM group, from 9.1\u00b11.0% (76\u00b111\u2009mmol\/mol) to 8.0\u00b11.2% (64\u00b113\u2009mmol\/mol) in the CGM group and from 9.0\u00b10.9% (75\u00b110\u2009mmol\/mol) to 8.5\u00b11.5% (69\u00b116\u2009mmol\/mol) in the BGM group (adjusted difference, \u22120.6% (95% CI \u20130.9% to \u22120.3%); \u22126.6\u2009mmol\/mol (95% CI \u201310.2 to \u20132.9), p&lt;0.001). Mean time spent in range 70\u2013180\u2009mg\/dL (3.9\u201310.0\u2009mmol\/L) increased significantly more in the CGM group than the BGM group (adjusted difference, +9.3% (95% CI 2.1% to 16.4%), p&lt;0.001). There also was a greater reduction in mean time &gt;250\u2009mg\/dL (&gt;13.9\u2009mmol\/L) with CGM (adjusted difference, \u22125.8% (95% CI \u221210.4% to \u22121.2%), p&lt;0.001) without an increase in time &lt;70\u2009mg\/dL (&lt;3.9\u2009mmol\/L). Mean weekly hypoglycemic event rate was lower with CGM than BGM (adjusted difference, \u22120.2 events per week (95% CI \u22120.4 to \u20130.1), p&lt;0.001). Further, in the CGM group, significant improvements in CGM metrics were observed during the first 7\u2009days of CGM use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In adults with basal insulin-treated T2D, use of CGM compared with BGM resulted in rapidly improved glycemic management, with a substantial reduction in HbA\n                      <jats:sub>1c<\/jats:sub>\n                      over 3 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03566693\">NCT03566693<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjdrc-2025-005469","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:41:12Z","timestamp":1762324872000},"page":"e005469","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Rapid improvements in glycemic management with use of continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin: 3-month analysis of the MOBILE study"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03566693","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Thomas W","family":"Martens","sequence":"first","affiliation":[{"name":"International Diabetes Center, HealthPartners Institute, Bloomington, Minnesota, USA"},{"name":"Department of Internal Medicine, Park Nicollet Health Services, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy W","family":"Beck","sequence":"additional","affiliation":[{"name":"Jaeb Center for Health Research, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8269-1401","authenticated-orcid":false,"given":"Corbin","family":"Griffen","sequence":"additional","affiliation":[{"name":"Dexcom, Inc, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6325-8090","authenticated-orcid":false,"given":"Junrui","family":"Di","sequence":"additional","affiliation":[{"name":"Dexcom, Inc, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3577-4009","authenticated-orcid":false,"given":"Karen","family":"Elkind-Hirsch","sequence":"additional","affiliation":[{"name":"Dexcom, Inc, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9576-9450","authenticated-orcid":false,"given":"Matthew L","family":"Johnson","sequence":"additional","affiliation":[{"name":"Dexcom, Inc, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R","family":"Castle","sequence":"additional","affiliation":[{"name":"Dexcom, Inc, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stayce E","family":"Beck","sequence":"additional","affiliation":[{"name":"Dexcom, Inc, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M","family":"Bergenstal","sequence":"additional","affiliation":[{"name":"International Diabetes Center, HealthPartners Institute, Bloomington, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2025110422402567000_13.6.e005469.1","unstructured":"World Health organization . Global report on diabetes. 2016."},{"key":"2025110422402567000_13.6.e005469.2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s13300-022-01254-8","article-title":"Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus","volume":"13","author":"Pleus","year":"2022","journal-title":"Diabetes Ther"},{"key":"2025110422402567000_13.6.e005469.3","doi-asserted-by":"publisher","DOI":"10.1177\/1932296816641433"},{"key":"2025110422402567000_13.6.e005469.4","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s13300-023-01399-0","article-title":"Gaps Remain for Achieving HbA1c Targets for People with Type 1 or Type 2 Diabetes Using Insulin: Results from NHANES 2009-2020","volume":"14","author":"Hankosky","year":"2023","journal-title":"Diabetes Ther"},{"key":"2025110422402567000_13.6.e005469.5","unstructured":"NHS Digital . National diabetes audit core report 1: care processes and treatment targets 2022-23, underlying data. 2023."},{"key":"2025110422402567000_13.6.e005469.6","unstructured":"Rewers A . Acute metabolic complications in diabetes. 2021."},{"key":"2025110422402567000_13.6.e005469.7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.tem.2020.01.007","article-title":"Chronic Diabetes Complications: The Need to Move beyond Classical Concepts","volume":"31","author":"Mauricio","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"2025110422402567000_13.6.e005469.8","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.3.476"},{"key":"2025110422402567000_13.6.e005469.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05787-2"},{"key":"2025110422402567000_13.6.e005469.10","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1600"},{"key":"2025110422402567000_13.6.e005469.11","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028"},{"key":"2025110422402567000_13.6.e005469.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19975"},{"key":"2025110422402567000_13.6.e005469.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19976"},{"key":"2025110422402567000_13.6.e005469.14","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2855"},{"key":"2025110422402567000_13.6.e005469.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6928"},{"key":"2025110422402567000_13.6.e005469.16","doi-asserted-by":"publisher","DOI":"10.1177\/1932296817704445"},{"key":"2025110422402567000_13.6.e005469.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805017"},{"key":"2025110422402567000_13.6.e005469.18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7444"},{"key":"2025110422402567000_13.6.e005469.19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/dc23-2194","article-title":"Comparing Continuous Glucose Monitoring and Blood Glucose Monitoring in Adults With Inadequately Controlled, Insulin-Treated Type 2 Diabetes (Steno2tech Study): A 12-Month, Single-Center, Randomized Controlled Trial","volume":"47","author":"Lind","year":"2024","journal-title":"Diabetes Care"},{"key":"2025110422402567000_13.6.e005469.20","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0494"},{"key":"2025110422402567000_13.6.e005469.21","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.2337\/dc25-S007","article-title":"7. Diabetes Technology: Standards of Care in Diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"2025110422402567000_13.6.e005469.22","doi-asserted-by":"crossref","first-page":"110718","DOI":"10.1016\/j.diabres.2023.110718","article-title":"Asia-Pacific consensus recommendations for application of continuous glucose monitoring in diabetes management","volume":"201","author":"Kong","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2025110422402567000_13.6.e005469.23","unstructured":"National Institute for Health and Care Excellence . Type 2 diabetes in adults: management [NG28]. NICE Guideline; 2022."},{"key":"2025110422402567000_13.6.e005469.24","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1089\/dia.2022.0274","article-title":"The Optimal Duration of a Run-In Period to Initiate Continuous Glucose Monitoring for a Randomized Trial","volume":"24","author":"Raghinaru","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"2025110422402567000_13.6.e005469.25","doi-asserted-by":"crossref","unstructured":"Craig Mallinckrodt GM , Lipkovich I , Ratitch B . Estimands, estimators and sensitivity analysis in clinical trials. New York: Chapman and Hall\/CRC, 2019.","DOI":"10.1201\/9780429488825"},{"key":"2025110422402567000_13.6.e005469.26","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1304"},{"key":"2025110422402567000_13.6.e005469.27","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.8.968"},{"key":"2025110422402567000_13.6.e005469.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107704"},{"key":"2025110422402567000_13.6.e005469.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401"},{"key":"2025110422402567000_13.6.e005469.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052187"},{"key":"2025110422402567000_13.6.e005469.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2025110422402567000_13.6.e005469.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"2025110422402567000_13.6.e005469.33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1089\/dia.2023.0141","article-title":"The Association of Time in Range and Diabetic Complications: The Evidence Is Strong","volume":"25","author":"Beck","year":"2023","journal-title":"Diabetes Technol Ther"},{"key":"2025110422402567000_13.6.e005469.34","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.2337\/dc21-2298","article-title":"Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial","volume":"45","author":"Lachin","year":"2022","journal-title":"Diabetes Care"},{"key":"2025110422402567000_13.6.e005469.35","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1444"},{"key":"2025110422402567000_13.6.e005469.36","first-page":"15","article-title":"Initiating continuous glucose monitoring is associated with improvements in glycemic control and reduced health care resource utilization for people with diabetes in a large US-insured population: A real-world evidence study","volume":"31","author":"Norman","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"key":"2025110422402567000_13.6.e005469.37","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s12325-024-02851-8","article-title":"Reduction in Diabetes-Related Hospitalizations and Medical Costs After Dexcom G6 Continuous Glucose Monitor Initiation in People with Type 2 Diabetes Using Intensive Insulin Therapy","volume":"41","author":"Hannah","year":"2024","journal-title":"Adv Ther"},{"key":"2025110422402567000_13.6.e005469.38","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1089\/dia.2021.0525","article-title":"Association Between Real-Time Continuous Glucose Monitor Use and Diabetes-Related Medical Costs for Patients with Type 2 Diabetes","volume":"24","author":"Norman","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"2025110422402567000_13.6.e005469.39","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1089\/dia.2024.0197","article-title":"Long-Term Improvements in Glycemic Control with Dexcom CGM Use in Adults with Noninsulin-Treated Type 2 Diabetes","volume":"26","author":"Layne","year":"2024","journal-title":"Diabetes Technol Ther"},{"key":"2025110422402567000_13.6.e005469.40","doi-asserted-by":"crossref","DOI":"10.1111\/dme.15348","article-title":"Real time continuous glucose monitoring in high-risk people with insulin-requiring type 2 diabetes: A randomised controlled trial","volume":"41","author":"Lever","year":"2024","journal-title":"Diabet Med"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2025-005469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:41:23Z","timestamp":1762324883000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2025-005469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjdrc-2025-005469"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2025-005469","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}